Edoardo Francini

Assistant Professor

Università degli Studi di Napoli Federico II

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Cancer Biology Cancer Biology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Edoardo Francini is an Assistant Professor at the Università degli Studi di Firenze in Italy. His research primarily focuses on cancer diagnostics, particularly in the use of circulating cell-free DNA (cfDNA) and its clinical implications across various types of cancer, including renal cell carcinoma and non-small-cell lung cancer. He has published extensively on topics such as hypoxia-inducible factors in renal cancer and the prognostic value of tumor-infiltrating lymphocytes in colon cancer.

Articles (7)

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (2)

Giuseppe Nicolò Fanelli

University of Pisa

ITALY

View details

Steven Balk

Harvard University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Edoardo Francini

Research Interests

Explore related searches

Contact this professor

About

Articles (7)

Cell-Free DNA: Unveiling the Future of Cancer Diagnostics and Monitoring

Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted Therapies

Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study

Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer

Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases

The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study

Collaborators (2)

Giuseppe Nicolò Fanelli

Steven Balk

Make your next move.